The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Recipharm acquires Arranta Bio
Finance

Recipharm acquires Arranta Bio

FEB 18, 2022
Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
Biotech Showcase

Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132

FEB 17, 2022
EasyBioM® – Data Visualisation in a few clicks
Biofortis

EasyBioM® – Data Visualisation in a few clicks

FEB 16, 2022
Fecal implants drive behavioral and cognitive changes in Alzheimer’s model
Gut-Brain Axis

Fecal implants drive behavioral and cognitive changes in Alzheimer’s model

FEB 12, 2022
New “vertical map” of airborne microorganisms indicates how global warming will impact global ecosystems
Pharma & Human Health

New “vertical map” of airborne microorganisms indicates how global warming will impact global ecosystems

FEB 11, 2022
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development
Finance

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

FEB 10, 2022
MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies
Clinical & Manufacturing

MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies

FEB 9, 2022
BioGaia’s probiotic reduces inflammation in patients with diverticulitis
Biotics and Supplements

BioGaia’s probiotic reduces inflammation in patients with diverticulitis

FEB 9, 2022
ELIGO v SNIPR: a reflection on IP strategies in a competitive environment
Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

FEB 7, 2022
Microbiome of mother’s vagina may affect infant mortality risk and baby’s development
Pharma & Human Health

Microbiome of mother’s vagina may affect infant mortality risk and baby’s development

FEB 4, 2022
Ferring takes pre-emptive action in IP dispute with Finch
Editor's Choice

Ferring takes pre-emptive action in IP dispute with Finch

FEB 2, 2022